Compare Dr. Reddys with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TORRENT PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TORRENT PHARMA DR. REDDYS LAB/
TORRENT PHARMA
 
P/E (TTM) x 34.8 35.1 99.2% View Chart
P/BV x 4.8 8.9 53.6% View Chart
Dividend Yield % 0.6 0.7 81.3%  

Financials

 DR. REDDYS LAB   TORRENT PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
TORRENT PHARMA
Mar-19
DR. REDDYS LAB/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3631,964 171.2%   
Low Rs2,3521,245 188.9%   
Sales per share (Unadj.) Rs1,054.2453.4 232.5%  
Earnings per share (Unadj.) Rs121.925.8 472.9%  
Cash flow per share (Unadj.) Rs190.262.3 305.4%  
Dividends per share (Unadj.) Rs25.0017.00 147.1%  
Dividend yield (eoy) %0.91.1 82.6%  
Book value per share (Unadj.) Rs938.7279.2 336.2%  
Shares outstanding (eoy) m166.17169.22 98.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.73.5 76.6%   
Avg P/E ratio x23.462.2 37.7%  
P/CF ratio (eoy) x15.025.8 58.3%  
Price / Book Value ratio x3.05.7 53.0%  
Dividend payout %20.565.9 31.1%   
Avg Mkt Cap Rs m474,831271,513 174.9%   
No. of employees `00021.713.6 159.2%   
Total wages/salary Rs m33,80214,038 240.8%   
Avg. sales/employee Rs Th8,091.05,642.6 143.4%   
Avg. wages/employee Rs Th1,561.31,032.4 151.2%   
Avg. net profit/employee Rs Th935.8320.9 291.6%   
INCOME DATA
Net Sales Rs m175,17076,728 228.3%  
Other income Rs m6,206571 1,087.8%   
Total revenues Rs m181,37677,299 234.6%   
Gross profit Rs m24,42119,831 123.1%  
Depreciation Rs m11,3486,177 183.7%   
Interest Rs m9835,038 19.5%   
Profit before tax Rs m18,2969,187 199.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m-1,4031,254 -111.9%   
Profit after tax Rs m20,2604,363 464.3%  
Gross profit margin %13.925.8 53.9%  
Effective tax rate %-7.713.6 -56.2%   
Net profit margin %11.65.7 203.4%  
BALANCE SHEET DATA
Current assets Rs m125,99150,375 250.1%   
Current liabilities Rs m72,14151,653 139.7%   
Net working cap to sales %30.7-1.7 -1,845.9%  
Current ratio x1.71.0 179.1%  
Inventory Days Days7392 79.4%  
Debtors Days Days10568 153.4%  
Net fixed assets Rs m83,85483,648 100.2%   
Share capital Rs m831846 98.2%   
"Free" reserves Rs m155,15746,397 334.4%   
Net worth Rs m155,98847,244 330.2%   
Long term debt Rs m1,30439,129 3.3%   
Total assets Rs m232,253141,209 164.5%  
Interest coverage x19.62.8 694.6%   
Debt to equity ratio x00.8 1.0%  
Sales to assets ratio x0.80.5 138.8%   
Return on assets %9.16.7 137.4%  
Return on equity %13.09.2 140.6%  
Return on capital %12.612.3 102.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,19322,103 380.9%   
Fx outflow Rs m39,6165,522 717.5%   
Net fx Rs m44,57716,581 268.8%   
CASH FLOW
From Operations Rs m29,84117,981 166.0%  
From Investments Rs m-4,923-2,413 204.0%  
From Financial Activity Rs m-25,159-13,145 191.4%  
Net Cashflow Rs m-2662,380 -11.2%  

Share Holding

Indian Promoters % 25.5 71.5 35.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 7.0 76.9%  
FIIs % 35.3 12.6 280.2%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.8 173.9%  
Shareholders   75,885 26,511 286.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 441 Points Lower; Nifty Settles Below 15,000-Mark(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day lower.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 5, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - PFIZER COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS